歡迎您,來(lái)到青旗(上海)生物技術(shù)發(fā)展有限公司!
Product category
Related articles
簡(jiǎn)要描述:青旗(上海)生物技術(shù)發(fā)展有限公司,總部位于上海浦東新區(qū),依托本地高校資源,逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺(tái),在標(biāo)準(zhǔn)化細(xì)胞庫(kù)建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營(yíng)原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測(cè)等科研產(chǎn)品與服務(wù)。我們秉承對(duì)用戶(hù)負(fù)責(zé)的態(tài)度,以對(duì)科研的高度嚴(yán)謹(jǐn),以嚴(yán)格的質(zhì)量控制,為廣大生物醫(yī)學(xué)科研用戶(hù)提供更優(yōu)質(zhì)的服務(wù)!
更新時(shí)間:2021-05-25
廠商性質(zhì):生產(chǎn)廠家
瀏覽次數(shù):326
品牌 | 其他品牌 | 貨號(hào) | BFN60811444 |
---|---|---|---|
規(guī)格 | T25培養(yǎng)瓶x1 1.5ml凍存管x2 | 供貨周期 | 現(xiàn)貨 |
主要用途 | 僅供科研 | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,生物產(chǎn)業(yè) |
細(xì)胞名稱(chēng) | 人膀胱癌細(xì)胞SW1710 | ||
貨物編碼 | BFN60811444 | ||
產(chǎn)品規(guī)格 | T25培養(yǎng)瓶x1 | 1.5ml凍存管x2 | |
細(xì)胞數(shù)量 | 1x10^6 | 1x10^6 | |
保存溫度 | 37℃ | -198℃ | |
運(yùn)輸方式 | 常溫保溫運(yùn)輸 | 干冰運(yùn)輸 | |
安全等級(jí) | 1 | ||
用途限制 | 僅供科研 3類(lèi) |
培養(yǎng)體系 | DMEM(HYCLONE SH30022.01)+10%FBS+1%三抗 | ||
培養(yǎng)溫度 | 37℃ | 二氧化碳濃度 | 5% |
簡(jiǎn)介 | 人膀胱癌細(xì)胞SW1710取自84歲女性供體 | ||
注釋 | Part of: BLA-40 bladder carcinoma cell line panel. Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: UBC-40 urothelial bladder cancer cell line index. From: Scott and White Clinic; Temple; USA. Doubling time: ~25-32 hours (DSMZ). Microsatellite instability: Stable (MSS) (Sanger). Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: SNP array analysis. Omics: Transcriptome analysis. | ||
基因突變 | TERT c.228C>T (-124C>T); in promoter (PubMed=24035680). | ||
HLA信息 |
| ||
STR信息 | Amelogenin X CSF1PO 11,12 D5S818 12 D7S820 8,11 D13S317 12 D16S539 8,11 TH01 7,10 (Cosmic-CLP) 7,8,9.3 (DSMZ) 7,9.3 (PubMed=27270441) TPOX 9,11 vWA 16,17
| ||
參考文獻(xiàn) | PubMed=27270441; DOI=10.1038/onc.2016.172 Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K., Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene 36:35-46(2017)
PubMed=29732388; DOI=10.3233/BLC-180167 Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D. Systematic review: characteristics and preclinical uses of bladder cancer cell lines. Bladder Cancer 4:169-183(2018)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) |